Clinical Trial News and Research

RSS

Concomitant physical symptoms in patients with depression and anxiety associated with poorer prognosis

This study, published in the last 2010 issue of Psychotherapy and Psychosomatics, indicate that concomitant physical symptoms in patients with depression and anxiety are associated with a poorer prognosis of symptoms of depression and anxiety and that it might prove worthwhile to pay attention to the role of multiple physical symptoms in the process of tailoring interventions to meet the needs of depressed and anxious patients in primary care.

19 Jan 2011

Curcumin and dye brilliant blue G may help block dangerous swelling in TBI

An old Indian spice and a dye whose cousin makes sports drinks blue are pointing scientists toward better treatment of traumatic brain injuries.

19 Jan 2011

Almac reports substantial progress in transitioning operations to new headquarters

Almac is making substantial progress in transitioning operations to its new headquarters in Souderton, PA, especially in the area of distribution. The new facility has been successfully shipping clinical trial materials since November, and has recently seen an increase in shipment volumes due to the added efficiencies the new building provides.

19 Jan 2011

Magnetic maneuverable capsule safe and well-tolerated in the stomach

A study from researchers in Germany showed that magnetic maneuvering of a modified capsule endoscope in the stomach of healthy volunteers under clinical conditions is safe, well-tolerated, and technically feasible. Maneuverability of the capsule within the stomach was excellent and visualization of the gastric mucosa, the inner lining of the stomach, was satisfactory in the majority of subjects.

19 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Medtronic recieves conditional approval from FDA to modify CoreValve U.S. Pivotal Clinical Trial

Medtronic, today announced it has received conditional approval from the U.S. Food and Drug Administration to modify its CoreValve U.S. Pivotal Clinical Trial.

19 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Study investigators today reported initial data from Cook Medical's REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company's balloon-expandable renal stent for the treatment of renal artery stenosis. The data, presented by Robert Bersin, M.D., at ISET 2011, reveal a nine-month primary patency rate of 89.5 percent and a 97 percent rate of successful delivery and deployment of the stent.

18 Jan 2011

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron and Bayer HealthCare announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.

18 Jan 2011

Researchers find kidney-specific gene defects may increase risk of heart failure

Scientists have identified the first DNA sequence variant common in the population that is not only associated with an increased risk of heart failure, but appears to play a role in causing it.

18 Jan 2011

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

The science team from Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, met with the Data Safety Monitoring Board (DSMB), an independent group of medical experts, yesterday and received approval to dose all remaining patients in the initial forty (40) patient leg of the 120-patient, cervical dysplasia clinical trial being conducted in the United States.

14 Jan 2011

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

Journal of the National Cancer Institute: Projections Of The Cost Of Cancer Care In The United States: 2010-2020 - "By combining cancer prevalence with average annual costs of cancer care by phase of care and tumor site for 13 cancers in men and 16 cancers in women" and "all cancer sites combined," the authors project there will be just over 18 million cancer survivors in 2020 compared to 13.8 million survivors in 2010.

14 Jan 2011

CINJ clinical trial explores anti-malaria drug against melanoma

Building upon recent laboratory discoveries on resistance by cancer cells to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are conducting a clinical trial that further explores how to prevent that action.

14 Jan 2011

BIOTRONIK announces FDA IDE approval and first patient enrollment for TOCCASTAR clinical trial

BIOTRONIK SE Co. & KG highlights two key milestones toward receiving premarket approval (PMA) of the TactiCath, a novel technology for treating atrial fibrillation (AF): FDA IDE (investigational device exemption) approval and the first patient enrollment of the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical trial.

14 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease

In a study published in December 2010, in Hypertension, a journal of the American Heart Association, investigators have shown that early treatment with blood pressure-lowering medications provides a long-term benefit of reducing the risk of death from cardiovascular disease.

13 Jan 2011

Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women

Researchers at the University of North Carolina at Chapel Hill have launched a new clinical trial to determine if estrogen replacement therapy may help prevent depression and cardiovascular illness in women between the ages of 45 and 55.

13 Jan 2011

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

13 Jan 2011

Clinical Trial News and Research

Concomitant physical symptoms in patients with depression and anxiety associated with poorer prognosis

Curcumin and dye brilliant blue G may help block dangerous swelling in TBI

Almac reports substantial progress in transitioning operations to new headquarters

Magnetic maneuverable capsule safe and well-tolerated in the stomach

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Medtronic recieves conditional approval from FDA to modify CoreValve U.S. Pivotal Clinical Trial

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Researchers find kidney-specific gene defects may increase risk of heart failure

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

CINJ clinical trial explores anti-malaria drug against melanoma

BIOTRONIK announces FDA IDE approval and first patient enrollment for TOCCASTAR clinical trial

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease

Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer